SOTIO, owned by PPF Group, is a biotechnology company focused on clinical-stage research and development of innovative medicines for cancer.
SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit.
SOTIO was founded in 2010 and in 2012 became part of PPF Group, owned by Petr Kellner. The company is headquartered in Prague, Czech Republic, with operations across Europe, North America, and Asia.
SOTIO's robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a proprietary technology designed to improve on the efficacy of CAR T therapies and a new generation of potent and stable antibody-drug conjugates (ADCs).
SOTIO is building a pipeline of oncology programs by pursuing promising early-stage candidates backed by strong science through strategic licensing, M&A and in-house discovery efforts.
SOTIO has established the key capabilities required for research, preclinical and clinical development, commercial planning, and market access, with the goal to rapidly advance the programs in their portfolio through clinical development towards commercialization.
SOTIO has raised up to €280M ($317M) in new funding on Dec 02, 2021. The money will be used to expand and advance its clinical pipeline, including its lead asset SOT101, an IL-15 superagonist, and three new clinical programs, until the end of 2023.